SCHEMBL23536141

SCHEMBL23536141

CC(c1cccc(F)c1N1CCC(CN2CCC(F)(F)CC2)CC1)S(=O)(=O)c1ccc(S(=O)(=O)N(C)C)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.34
KDM2B Q8NHM5 2/20 0.34
HTR1A P08908 3/20 0.33
DRD2 P14416 2/20 0.33
HTR2A P28223 2/20 0.33
HTR7 P34969 2/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
RORC P51449 1/20 0.32
MC4R P32245 2/20 0.32
MCOLN2 Q8IZK6 1/20 0.32
TPSAB1 Q15661 1/20 0.31
MC5R P33032 1/20 0.31
MC3R P41968 1/20 0.31
GHSR Q92847 1/20 0.31
TRPA1 O75762 1/20 0.31
C5AR1 P21730 1/20 0.31
MELK Q14680 1/20 0.30
GCK P35557 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23555263 0.83 ALDH1A1 (0.39) MEN1HTR1ADRD2HTR2AHTR7
SCHEMBL23536515 0.82 MEN1 (0.34) MEN1KDM2BHTR1AKDM4ELMNA
SCHEMBL29931917 0.81 MCOLN2 (0.35) HTR1ADRD2HTR2AHTR7LMNA
SCHEMBL23536174 0.78 PSEN1 (0.33) MEN1KDM4ELMNAMC4RMC5R
SCHEMBL23536172 0.78 PSEN1 (0.33) MEN1KDM4ELMNAMC4RMC5R
SCHEMBL23536016 0.77 KMT2A (0.47) MEN1KDM4ELMNAL3MBTL1
SCHEMBL23536275 0.74 GPR119 (0.34) MC4RMCOLN2
SCHEMBL23554982 0.74 ALDH1A1 (0.32) MEN1KDM2BKDM4ELMNAL3MBTL1
SCHEMBL29948471 0.74 ALDH1A1 (0.32) MEN1KDM2BKDM4ELMNAL3MBTL1
SCHEMBL29932238 0.71 LMNA (0.38) MEN1HTR1ADRD2HTR2AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230104936-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-04-06 US disclosed
EP-4076423-A1 TRPML MODULATORS Casma Therapeutics, Inc. (US) 2022-10-26 EP disclosed
WO-2021127337-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. (US) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230104936-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 MEN1 782/4885KDM2B 3104/4885HTR1A 377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.